News

Ready to pack your bags for a little R&R? Here are a few favorite spots recommended by industry leaders.

A new study provides new insights into the epidemiology of breast cancer among the most prominent Asian-American ethnic groups in California.

FDA recently approved the first new treatment for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, in more than 20 years.

Walmart, CVS Health, and a number of other healthcare organizations are supporting a new multi-million dollar consumer campaign to combat high prescription drug prices.

For the first time, Managed Healthcare Executive has identified 10 emerging healthcare industry leaders. Their backgrounds, expertise, and contributions represent four managed care sectors: pharmacy, health plans, health systems, and technology.

Successful organizations nurture strong performers and help them bridge the gap between the present and the future.

Successful organizations nurture strong performers and help them bridge the gap between the present and the future.

Stakeholders say CMS’ hospital overall star ratings are biased and can unfairly damage the reputations of good hospitals.

A new study from researchers from the Minneapolis VA Health Care System has interesting findings.

Patients are demanding more from payers and providers. Here’s how technology can help.

Jonathan Linkous of the American Telemedicine Association identifies the trends to watch

Here's how five health plans are successfully approaching palliative care.

Diabetes accounts for one out of every 10 American healthcare dollars spent, but new national programs are helping address this issue.

Here are 3 ways that technology can tap into the powerful network of non-clinical patient influencers who will ultimately impact a patient’s healthcare decisions and behavioral changes.

Late last week, FDA approved a new drug to treat acute myeloid leukemia (AML), the first treatment for Batten disease, and expanded the use of a current drug to treat liver cancer.

Many healthcare organizations’ cost transparency tools fall short on goals and member usage because they fail to incorporate these critical elements.

A new abuse-deterrent painkiller - oxycodone hydrochloride (RoxyBond, Inspirion Delivery Services) - will be available soon after receiving FDA approval.

Payers have unmet needs in the changing hepatitis C (HCV) space, according to a recent survey. The survey, from Precision for Value, highlights what can be done to encourage payers to ease coverage policies for these drugs in the next wave of HCV treatment.

Study: PCSK9 inhibitors are being rejected by insurers at very high rates even in high-risk patients like those with familial hypercholesterolemia.

Two University of Massachusetts Medical School pharmacists make the case to reform or align 42 CFR Part 2 with HIPAA to better serve patients with substance use disorder.

A Cleveland Clinic study examines the mortality burden of modifiable behavioral risk factors such as obesity, diabetes, tobacco use, high blood pressure and high cholesterol.

New findings reveal this genetic test to assess breast cancer risk could be more effective than others.

In what is expected to produce hefty saving for rheumatoid arthritis patients and the healthcare system, FDA approved the second biosimilar to Remicade (Johnson & Johnson).

A Gallup-Healthways poll shows it will be important to monitor the uninsured trends in the coming months as the ACA hangs in the balance.

FDA said this week that it is restricting the use of codeine and tramadol medicines in children. The drug’s labels will now include a contraindication that codeine should not be used to treat pain or cough, and that tramadol should not be used to treat pain, in children younger than 12 years.

A new Commonwealth Fund survey on how Medicaid changes could affect this population, has experts weighing in on ways to resolve the healthcare disconnect.

Our policy analyst explains the concept of invisible high-risk pools, and explains how they might affect health reform.

Decades of research has led to a flurry of new warnings.